{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:30:51Z","timestamp":1791189051541,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1124\/jpet.108.138776","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T21:30:57Z","timestamp":1212615057000},"page":"754-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["MF63 [2-(6-Chloro-1 H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation"],"prefix":"10.1016","volume":"326","author":[{"given":"Daigen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patsy","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Giroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Guiral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"M\u00e9thot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Audoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Riendeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.108.138776_bib1","doi-asserted-by":"crossref","unstructured":"Abe M, Oka T, Hori T, and Takahashi S (2001) Prostanoids in the preoptic hypothalamus mediate systemic lipopolysaccharide-induced hyperalgesia in rats. Brain Res 916: 41-49.","DOI":"10.1016\/S0006-8993(01)02861-X"},{"key":"10.1124\/jpet.108.138776_bib2","doi-asserted-by":"crossref","unstructured":"Ahmadi S, Lippross S, Neuhuber WL, and Zeilhofer HU (2002) PGE(2) selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 5: 34-40.","DOI":"10.1038\/nn778"},{"key":"10.1124\/jpet.108.138776_bib3","doi-asserted-by":"crossref","unstructured":"Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, and M\u00e9thot N (2004) Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile. J Biol Chem 279: 23229-23237.","DOI":"10.1074\/jbc.M400443200"},{"key":"10.1124\/jpet.108.138776_bib4","doi-asserted-by":"crossref","unstructured":"Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, and Chan CC (1996) A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45: 68-74.","DOI":"10.1007\/BF02265118"},{"key":"10.1124\/jpet.108.138776_bib5","doi-asserted-by":"crossref","unstructured":"Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der HD, et al. (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771-1781.","DOI":"10.1016\/S0140-6736(06)69666-9"},{"key":"10.1124\/jpet.108.138776_bib6","doi-asserted-by":"crossref","unstructured":"Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, and Fitzgerald GA (2006) Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 116: 1391-1399.","DOI":"10.1172\/JCI27540"},{"key":"10.1124\/jpet.108.138776_bib7","doi-asserted-by":"crossref","unstructured":"Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, et al. (2008) MF498, [N-{[4-(5,9-diethoxy-6-oxo-6,8-dihydro-7 H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective EP4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther 325: 425-434.","DOI":"10.1124\/jpet.107.134510"},{"key":"10.1124\/jpet.108.138776_bib8","doi-asserted-by":"crossref","unstructured":"C\u00f4t\u00e9 B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, et al. (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17: 6816-6820.","DOI":"10.1016\/j.bmcl.2007.10.033"},{"key":"10.1124\/jpet.108.138776_bib9","doi-asserted-by":"crossref","unstructured":"Couzin J (2005) Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Science 307: 1183-1185.","DOI":"10.1126\/science.307.5713.1183a"},{"key":"10.1124\/jpet.108.138776_bib10","doi-asserted-by":"crossref","unstructured":"Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, and Ericsson-Dahlstrand A (2001) Inflammatory response: pathway across the blood-brain barrier. Nature 410: 430-431.","DOI":"10.1038\/35068632"},{"key":"10.1124\/jpet.108.138776_bib11","doi-asserted-by":"crossref","unstructured":"Engblom D, Saha S, Engstr\u00f6m L, Westman M, Audoly LP, Jakobsson PJ, and Blomqvist A (2003) Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat Neurosci 6: 1137-1138.","DOI":"10.1038\/nn1137"},{"key":"10.1124\/jpet.108.138776_bib12","doi-asserted-by":"crossref","unstructured":"Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711.","DOI":"10.1056\/NEJMp048288"},{"key":"10.1124\/jpet.108.138776_bib13","doi-asserted-by":"crossref","unstructured":"Francois H, Facemire C, Kumar A, Audoly L, Koller B, and Coffman T (2007) Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 18: 1466-1475.","DOI":"10.1681\/ASN.2006040343"},{"key":"10.1124\/jpet.108.138776_bib14","doi-asserted-by":"crossref","unstructured":"Guay J, Bateman K, Gordon R, Mancini J, and Riendeau D (2004) Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1. J Biol Chem 279: 24866-24872.","DOI":"10.1074\/jbc.M403106200"},{"key":"10.1124\/jpet.108.138776_bib15","doi-asserted-by":"crossref","unstructured":"Heinricher MM, Martenson ME, and Neubert MJ (2004) Prostaglandin E2 in the midbrain periaqueductal gray produces hyperalgesia and activates pain-modulating circuitry in the rostral ventromedial medulla. Pain 110: 419-426.","DOI":"10.1016\/j.pain.2004.04.026"},{"key":"10.1124\/jpet.108.138776_bib16","doi-asserted-by":"crossref","unstructured":"Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, and Bolognese JA (2000) A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 109: 201-206.","DOI":"10.1016\/S0002-9343(00)00470-8"},{"key":"10.1124\/jpet.108.138776_bib17","doi-asserted-by":"crossref","unstructured":"Jakobsson PJ, Thor\u00e9n S, Morgenstern R, and Samuelsson B (1999) Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96: 7220-7225.","DOI":"10.1073\/pnas.96.13.7220"},{"key":"10.1124\/jpet.108.138776_bib18","doi-asserted-by":"crossref","unstructured":"Jia Z, Zhang A, Zhang H, Dong Z, and Yang T (2006) Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99: 1243-1251.","DOI":"10.1161\/01.RES.0000251306.40546.08"},{"key":"10.1124\/jpet.108.138776_bib19","doi-asserted-by":"crossref","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, and Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332: 1302-1308.","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"10.1124\/jpet.108.138776_bib20","doi-asserted-by":"crossref","unstructured":"Kudo I and Murakami M (2005) Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 38: 633-638.","DOI":"10.5483\/BMBRep.2005.38.6.633"},{"key":"10.1124\/jpet.108.138776_bib21","doi-asserted-by":"crossref","unstructured":"Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, and Bolognese J (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117: 776-783.","DOI":"10.1016\/S0016-5085(99)70334-3"},{"key":"10.1124\/jpet.108.138776_bib22","doi-asserted-by":"crossref","unstructured":"Li S, Wang Y, Matsumura K, Ballou LR, Morham SG, and Blatteis CM (1999) The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-\/-), but not in cyclooxygenase-1(-\/-) mice. Brain Res 825: 86-94.","DOI":"10.1016\/S0006-8993(99)01225-1"},{"key":"10.1124\/jpet.108.138776_bib23","doi-asserted-by":"crossref","unstructured":"Matsumoto H, Naraba H, Murakami M, Kudo I, Yamaki K, Ueno A, and Oh-ishi S (1997) Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide-stimulated rat peritoneal macrophages. Biochem Biophys Res Commun 230: 110-114.","DOI":"10.1006\/bbrc.1996.5894"},{"key":"10.1124\/jpet.108.138776_bib24","doi-asserted-by":"crossref","unstructured":"Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388: 678-682.","DOI":"10.1038\/41780"},{"key":"10.1124\/jpet.108.138776_bib25","doi-asserted-by":"crossref","unstructured":"Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, and Ballou LR (2000) The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 43: 2687-2693.","DOI":"10.1002\/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9"},{"key":"10.1124\/jpet.108.138776_bib26","doi-asserted-by":"crossref","unstructured":"Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, and Takada J (2007) CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322: 686-694.","DOI":"10.1124\/jpet.107.122010"},{"key":"10.1124\/jpet.108.138776_bib27","doi-asserted-by":"crossref","unstructured":"Portanova JP, Zhang Y, Anderson GD, Hauser SD, Masferrer JL, Seibert K, Gregory SA, and Isakson PC (1996) Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 184: 883-891.","DOI":"10.1084\/jem.184.3.883"},{"key":"10.1124\/jpet.108.138776_bib28","doi-asserted-by":"crossref","unstructured":"Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC, Riendeau D, and Audoly LP (2006) Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther 319: 1043-1050.","DOI":"10.1124\/jpet.106.110387"},{"key":"10.1124\/jpet.108.138776_bib29","doi-asserted-by":"crossref","unstructured":"Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, M\u00e9thot N, et al. (2005) Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett 15: 3352-3355.","DOI":"10.1016\/j.bmcl.2005.05.027"},{"key":"10.1124\/jpet.108.138776_bib30","doi-asserted-by":"crossref","unstructured":"Riendeau D, Percival MD, Brideau C, Charleson S, Dub\u00e9 D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, et al. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296: 558-566.","DOI":"10.1016\/S0022-3565(24)38776-2"},{"key":"10.1124\/jpet.108.138776_bib31","doi-asserted-by":"crossref","unstructured":"Rowland SE, Clark P, Gordon R, Mullen AK, Guay J, Dufresne L, Brideau C, Cote B, Ducharme Y, Mancini J, et al. (2007) Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5 H)-furanone], in multiple preclinical species. Eur J Pharmacol 560: 216-224.","DOI":"10.1016\/j.ejphar.2007.01.008"},{"key":"10.1124\/jpet.108.138776_bib32","doi-asserted-by":"crossref","unstructured":"Samuelsson B, Morgenstern R, and Jakobsson PJ (2007) Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224.","DOI":"10.1124\/pr.59.3.1"},{"key":"10.1124\/jpet.108.138776_bib33","doi-asserted-by":"crossref","unstructured":"Scheiman JM (2003) Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Des 9: 2197-2206.","DOI":"10.2174\/1381612033454018"},{"key":"10.1124\/jpet.108.138776_bib34","doi-asserted-by":"crossref","unstructured":"Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, and Bjarnason I (2000) COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47: 527-532.","DOI":"10.1136\/gut.47.4.527"},{"key":"10.1124\/jpet.108.138776_bib35","doi-asserted-by":"crossref","unstructured":"Stichtenoth DO, Thor\u00e9n S, Bian H, Peters-Golden M, Jakobsson PJ, and Crofford LJ (2001) Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167: 469-474.","DOI":"10.4049\/jimmunol.167.1.469"},{"key":"10.1124\/jpet.108.138776_bib36","doi-asserted-by":"crossref","unstructured":"Taiwo YO, Goetzl EJ, and Levine JD (1987) Hyperalgesia onset latency suggests a hierarchy of action. Brain Res 423: 333-337.","DOI":"10.1016\/0006-8993(87)90858-4"},{"key":"10.1124\/jpet.108.138776_bib37","doi-asserted-by":"crossref","unstructured":"Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, et al. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100: 9044-9049.","DOI":"10.1073\/pnas.1332766100"},{"key":"10.1124\/jpet.108.138776_bib38","doi-asserted-by":"crossref","unstructured":"Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, et al. (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395: 281-284.","DOI":"10.1038\/26233"},{"key":"10.1124\/jpet.108.138776_bib39","doi-asserted-by":"crossref","unstructured":"Whittle BJ and Vane JR (1984) A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs. Arch Toxicol Suppl 7: 315-322.","DOI":"10.1007\/978-3-642-69132-4_54"},{"key":"10.1124\/jpet.108.138776_bib40","doi-asserted-by":"crossref","unstructured":"Yaksh TL, Kokotos G, Svensson CI, Stephens D, Kokotos CG, Fitzsimmons B, Hadjipavlou-Litina D, Hua XY, and Dennis EA (2006) Systemic and intrathecal effects of a novel series of phospholipase A2 inhibitors on hyperalgesia and spinal prostaglandin E2 release. J Pharmacol Exp Ther 316: 466-475.","DOI":"10.1124\/jpet.105.091686"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524345744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524345744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.108.138776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:43:30Z","timestamp":1739987010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524345744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0022356524345744"],"URL":"https:\/\/doi.org\/10.1124\/jpet.108.138776","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1124203.581345","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MF63 [2-(6-Chloro-1 H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a Selective Microsomal Prostaglandin E Synthase-1 Inhibitor, Relieves Pyresis and Pain in Preclinical Models of Inflammation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.108.138776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}